umptions contained in the foregoing are forward-looking statements.
These forward looking statements involve a number of risks and
uncertainties that could cause actual future results to differ materially
from those anticipated in the forward looking statements, Actual results
could differ materially from such statements expressed or implied herein.
Factors that might cause such a difference include, among others, the
company's ability to continue gaining new customers, offer new types of
tests, and otherwise implement its business plan. As a result, this press
release should be read in conjunction with the company's periodic filings
with the SEC.
NeoGenomics, Inc.
CONSOLIDATED BALANCE SHEET AS OF
June 30, 2008
(unaudited)
ASSETS
CURRENT ASSETS $ 5,194,477
PROPERTY AND EQUIPMENT (net of
accumulated depreciation of $1,185,750) 2,215,613
OTHER ASSETS 255,566
TOTAL $ 7,665,656
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES $ 4,480,340
LONG TERM LIABILITIES 854,293
TOTAL LIABILITIES 5,334,633
STOCKHOLDERS' EQUITY 2,331,023
TOTAL $ 7,665,656
NeoGenomics, Inc.
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
For the For the
Three- Three- For the For the
'/>"/>
SOURCE NeoGenomics, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 Related medicine news :1.
NeoGenomics Announces Results for the 3rd Quarter 20072.
NeoGenomics, Inc. Schedules its Q3 07 Earnings Conference Call For Wednesday, November 14, 2007 at 11:00 AM3.
Cardiva Medical Announces Presentation at BMO Capital Markets 2008 Focus on Healthcare Conference4.
Lyriana Announces Antidepressants Now Linked to Declining Libido in Women 5.
Hologic Announces Third Quarter Fiscal 2008 Operating Results6.
VendorClear™ Announces Limited Release of New Products for Healthcare Facilities and Vendor Representatives7.
The Quantum Group Announces 2nd Statewide Contract8.
STERIS Corporation Announces Fiscal 2009 First Quarter Results9.
CutisPharma Announces Strategic Collaboration with Rite Aid Corporation10.
Cell Therapeutics, Inc. Announces $12 Million Equity Line of Credit11.
BrainLAB Announces 510(k) FDA Clearance of Monte Carlo Dose Engine for Stereotactic Radiosurgery and Radiation Therapy